SCHEMBL21363665

SCHEMBL21363665

CCCC(C)(C)c1cc2c(cc1Cc1ccc(COc3cc4c(cc3C(C)(C)C)OCO4)cc1)OCO2

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PDE5A O76074 1/20 0.34
MAOB P27338 1/20 0.34
SLC6A9 P48067 1/20 0.32
KCNH2 Q12809 1/20 0.32
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
CYP3A4 P08684 1/20 0.32
CALM1 P0DP23 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21363674 0.72 CDK4 (0.44) NPC1RAB9AKMT2ATDP1L3MBTL1
SCHEMBL21363676 0.67 SLC6A9 (0.45) KMT2AL3MBTL1MAOBSLC6A9KCNH2
SCHEMBL21363680 0.66 SLC6A9 (0.41) RAB9AKMT2AL3MBTL1MAOBSLC6A9
SCHEMBL21363788 0.66 MAOB (0.55) NPC1RAB9AKMT2ATDP1L3MBTL1
SCHEMBL21366597 0.65 MAOB (0.57) NPC1RAB9AKMT2ATDP1L3MBTL1
SCHEMBL21363672 0.64 MAOB (0.52) NPC1RAB9AKMT2ATDP1L3MBTL1
SCHEMBL11090673 0.63 EDNRA (0.43) RAB9A
SCHEMBL11091581 0.63 HTR2A (0.43) RAB9AKMT2ACYP3A4
SCHEMBL24008355 0.63 ALDH1A1 (0.40) L3MBTL1CYP3A4
SCHEMBL11090972 0.62 KMT2A (0.55) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019175712-A1 NEW USES FOR CATECHOL MOLECULES AS INHIBITORS TO GLUTATHIONE S-TRANSFERASE METABOLIC PATHWAYS BASF CORPORATION (US) 2019-09-19 WO disclosed
WO-2019175713-A1 NEW CATECHOL MOLECULES AND THEIR USE AS INHIBITORS TO P450 RELATED METABOLIC PATHWAYS BASF CORPORATION (US) 2019-09-19 WO disclosed